TrialBMJ open2024

Cost-effectiveness of C-reactive protein point of care testing for safely reducing antibiotic consumption for acute exacerbations of chronic obstructive pulmonary disease as part of the multicentre, parallel-arm, open, individually randomised, controlled PACE trial.

Bernadette Sewell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.